AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
SAB Biotherapeutics: Chardan Capital maintains a 'Buy' Rating, The Target Price is $20
ByAinvest
Thursday, May 15, 2025 12:00 pm ET1min read
Chardan Capital maintains 'Buy' rating on SAB Biotherapeutics(SABS).
The target price is unchanged and still at 20 .
[Recent Rating]
| Date | Agency | Change | Rating | Rating （previously） | Target Price | Target Price（previously） |
|---|---|---|---|---|---|---|
| 2025-05-15 | Chardan Capital | Maintains | Buy | Buy | $20 | $20 |
| 2025-05-14 | HC Wainwright & Co. | Assumes | Buy | -- | $10 | $-- |
[Recent Earning Results] Sab Biotherapeutics posted the Q1 of its 2025 financial results on 5/9/2025, reporting net income of USD -5.20 million in the first quarter, expanding 3.40% from USD -5.03 million year over year.
[Company Profile] SAB Biotherapeutics, Inc. is a company incorporated in Delaware on November 12, 2020. The Company is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer. SAB's versatile DiversitAb platform is applicable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB is currently advancing multiple clinical programs and has collaborations with the US government and global pharmaceutical companies.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet